News Related to Recurrence-Free Survival

Related coverage linked through entity extraction aliases.

Adjuvant Pembrolizumab Maintains Survival Benefit Without Raising New Melanoma Risk in Stage II Disease

Mar 03, 2026

Secondary analysis of KEYNOTE-716 trial finds adjuvant pembrolizumab improves recurrence-free survival in stage IIB/IIC melanoma without increasing new primary melanoma risk, while reducing non-melanoma skin cancers.

Moderna and Merck Report 5-Year Data for Melanoma Cancer Vaccine Intismeran Autogene

Dec 09, 2025

Moderna and Merck announced median five-year follow-up data showing intismeran autogene in combination with Keytruda reduced the risk of melanoma recurrence or death by 49% in high-risk patients following complete resection.